## Identification of the hepatitis C virus-the main cause of posttransfusion and sporadic non -A, non-B hepatitisand the development of a diagnostic serological test have allowed us to study possible recurrence of this type of hepatitis after liver transplantation. Six of 34 consecutive transplant
Early recurrence of hepatitis C virus infection after liver transplantation
โ Scribed by Lydia M. Petrovic
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 255 KB
- Volume
- 12
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.20942
No coin nor oath required. For personal study only.
โฆ Synopsis
- Early recurrence of hepatitis C is universal. 2. Typical histopathologic features of hepatitis C virus (HCV) and acute allograft rejection (AAR) exist. 3. Early recurrent HCV may be differentiated from AAR. 4. Liver biopsy plays a role in diagnosing HCV and AAR. 5. Risk factors for recurrent HCV should be known. 6. The natural history of recurrent HCV should be known. 7. The future role of ancillary studies beyond liver biopsy is assessed.
๐ SIMILAR VOLUMES
Chronic infection with the hepatitis C virus (HCV) is the most common reason for liver transplantation. We examined the results of laboratory tests for HCV on a cohort of patients who received a liver transplant between 1990 and 1994 at three large centers. Seven hundred twenty-two recipients and 60
Early histological recurrence of hepatitis C after liver transplantation (LT) has a negative impact on patient and graft survival. We report a case of histological recurrence of HCV occurring in the second week after LT. A 75-year-old woman with chronic HCV and hepatocellular carcinoma underwent LT
## Background: The value of immunohistochemical methods to identify hepatitis C virus antigen (HCVAg) in liver tissue has not been established. We have evaluated the significance of HCVAg expression in livers of patients with transplants and recurrent hepatitis C virus (HCV) infection. Methods: Fo
with treatment failures moving on to combination therapy (IFN/CMB). The primary difference between the two best strategies (IFN/CBM vs. CMB-G) was that the CMB-G strategy was more successful with those with genotype 1. Thus, the genotyping strategy reached more people with less responsive disease th